AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Athersys to Host First Quarter Financial Results Call

April 13, 2021 GMT

CLEVELAND--(BUSINESS WIRE)--Apr 13, 2021--

Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2021 financial results at approximately 4:00 PM Eastern Time on Thursday, May 6, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

Members of the management team will host the call as follows:

Date

May 6, 2021

Time

4:30 p.m. (Eastern Time)

Live webcast registration

Webcast link

Phone registration

Call registration link

We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID.

ADVERTISEMENT

A replay of the event will be available on the webcast link at www.athersys.com under the investors’ section approximately two hours after the call has ended. Shareholders may also call in for on-demand listening approximately three hours after the completion of the call until 11:59 PM Eastern Time on May 12, 2021, by dialing (800) 585-8367 or (416) 621-4642 and entering the conference code 4548767.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem ® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20210413005208/en/

CONTACT: Ivor Macleod

Chief Financial Officer

Tel: (216) 431-9900

ir@athersys.com

Karen Hunady

Director of Corporate Communications and Investor Relations

Tel: (216) 431-9900

khunady@athersys.com

David Schull

Russo Partners, LLC

Tel: (212) 845-4271 or (858) 717-2310

David.schull@russopartnersllc.com

KEYWORD: OHIO UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH STEM CELLS CARDIOLOGY BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE

SOURCE: Athersys, Inc.

Copyright Business Wire 2021.

PUB: 04/13/2021 07:00 AM/DISC: 04/13/2021 07:01 AM

http://www.businesswire.com/news/home/20210413005208/en